---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042317"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:21:13.971160+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q4 net income $49.9M, neffy sales $6.7M; pediatric approval expands market

## Summary
- neffy net product revenue $7.3M for FY2024 since Sep launch; Q4 net product revenue $6.7M.
- FDA approved neffy 1 mg for children 4+ and 15-30 kg on Mar 5, 2025; in pharmacies May 2025.
- Cash, equivalents & short-term investments $314M; operating runway at least 3 years.
- Payer coverage: >60% commercial lives under contract by end Q1 2025; >80% by early Q3.
- Phase 2b trial for chronic urticaria planned Q2 2025; topline data early 2026.

## SEC filing metadata
- accession: 0000950170-25-042317
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/0000950170-25-042317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042317
- JSON: https://secwatch.observer/filing/0000950170-25-042317.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.